Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Devonian Health GroupDVHGF 59 Forward PE Ratio is 0.00 as of Jul. 27, 2026. GuruFocus rates DVHGF with a GF Score™ of 59/100 and a GF Value™ of $2.00 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 353 Biotechnology companies, Devonian Health Group ranks worse than 283285.84% on this metric.
Devonian Health Group (OTCPK:DVHGF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Devonian Health Group Forward PE Ratio Related Terms
Devonian Health Group Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Devonian Health Group's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Devonian Health Group Forward PE Ratio Chart
Devonian Health Group Annual Data
Trend
Forward PE Ratio
Devonian Health Group Quarterly Data
Forward PE Ratio
DVHGF vs VRTX, REGN, RVMD: Forward PE Ratio Comparison
For the Biotechnology subindustry, Devonian Health Group's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's Forward PE Ratio falls into.
Devonian Health Group Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Devonian Health Group (DVHGF) has a Forward PE Ratio of 0.00 as of Jul. 27, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Devonian Health Group and its competitors. According to the industry distribution chart, Devonian Health Group ranks #999999 out of 353 companies in the Biotechnology industry.
Is Devonian Health Group's Forward PE Ratio too high?
Devonian Health Group's current Forward PE Ratio is 0.00. Based on the distribution chart, Devonian Health Group ranks #999999 out of 353 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Devonian Health Group has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #999999 out of 353 companies for Forward PE Ratio. This places Devonian Health Group in the lower half of its industry. The industry median Forward PE Ratio is 22.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.00, based on 353 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Devonian Health Group and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Devonian Health Group's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.00, compared to a current price of $7.00 — trading 250% above its estimated fair value. The current Forward PE Ratio is 0.00. Devonian Health Group's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current Forward PE Ratio is 0.00 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devonian Health Group (DVHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued.
The current stock price of $7.00 is trading 250% above its estimated GF Value™ of $2.00.
GuruFocus considers Devonian Health Group to be Significantly Overvalued.
Key valuation signals for DVHGF:
Forward PE Ratio: 0.00
GF Value™: $2.00 vs. price of $7.00 (250% above fair value)
No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
59GF Score
Get the complete analysis for DVHGF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVHGF has been successfully added to your 
